6月龄及以上人群使用二价mRNA COVID-19疫苗的临时建议——美国,2023年4月
美国CDC根据免疫实践咨询委员会(ACIP)的建议,在FDA修订紧急使用授权后,于2022年8月至2023年4月期间发布关于6月龄及以上人群使用二价mRNA COVID-19疫苗的临时建议。建议大多数人群接种单剂年龄适用的二价疫苗,免疫功能低下者和≥65岁成人可接种额外剂次。目前美国可用三种COVID-19疫苗:二价mRNA辉瑞-BioNTech疫苗、二价mRNA Moderna疫苗和单价佐剂蛋白亚单位Novavax疫苗。
要点
- FDA修订紧急使用授权,批准6岁及以上所有人使用单剂年龄适用的二价COVID-19疫苗。
- 批准6月龄至5岁儿童使用二价COVID-19疫苗剂次。
- 批准免疫功能低下者和≥65岁成人接种额外二价剂次。
核心结论
- 大多数人群接种单剂二价COVID-19疫苗,重症高风险人群接种额外剂次,有助于实施更简单、更灵活的推荐。
研究设计与样本
- CDC在ACIP指导下,根据FDA对紧急使用授权的修订,于2022年8月至2023年4月期间发布临时建议。
主要发现
- FDA修订紧急使用授权,批准6岁及以上所有人使用单剂年龄适用的二价COVID-19疫苗。
- FDA批准6月龄至5岁儿童使用二价COVID-19疫苗剂次。
- FDA批准免疫功能低下者和≥65岁成人接种额外二价剂次。
- 截至2022年8月31日,基于祖先SARS-CoV-2株的单价mRNA疫苗在美国不再被授权使用。
关键数值与推荐
- ACIP推荐使用二价mRNA辉瑞-BioNTech COVID-19疫苗。
- ACIP推荐使用二价mRNA Moderna COVID-19疫苗。
- ACIP推荐使用单价佐剂蛋白亚单位Novavax COVID-19疫苗。
临床怎么用
- 大多数人群接种单剂年龄适用的二价COVID-19疫苗,重症高风险人群接种额外剂次。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Throughout the national public health emergency declared in response to the COVID-19 pandemic, CDC, guided by the Advisory Committee on Immunization Practices (ACIP), has offered evidence-based recommendations for the use of COVID-19 vaccines in U.S. populations after each regulatory action by the Food and Drug Administration (FDA). During August 2022-April 2023, FDA amended its Emergency Use Authorizations (EUAs) to authorize the use of a single, age-appropriate, bivalent COVID-19 vaccine dose (i.e., containing components from the ancestral and Omicron BA.4/BA.5 strains in equal amounts) for all persons aged ≥6 years, use of bivalent COVID-19 vaccine doses for children aged 6 months-5 years, and additional bivalent doses for immunocompromised persons and adults aged ≥65 years (1). ACIP voted in September 2022 on the use of the bivalent vaccine, and CDC made recommendations after the September vote and subsequently, through April 2023, with input from ACIP. This transition to a single bivalent COVID-19 vaccine dose for most persons, with additional doses for persons at increased risk for severe disease, facilitates implementation of simpler, more flexible recommendations. Three COVID-19 vaccines are currently available for use in the United States and recommended by ACIP: 1) the bivalent mRNA Pfizer-BioNTech COVID-19 vaccine, 2) the bivalent mRNA Moderna COVID-19 vaccine, and 3) the monovalent adjuvanted, protein subunit-based Novavax COVID-19 vaccine.* As of August 31, 2022, monovalent mRNA vaccines based on the ancestral SARS-CoV-2 strain are no longer authorized for use in the United States (1).
引用
- Moulia DL, Wallace M, Roper LE, et al. Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months - United States, April 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37319020. doi:10.15585/mmwr.mm7224a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。